Collateral for a security interest recorded Feb 24, 2020 (HCR Collateral Management, LLC).
Term ended Oct 18, 2022 · High confidence
20-year base term ended Oct 18, 2022
Held by Nektar Therapeutics
Filed Jan 17, 2006 as application 11/332,964 · Granted Feb 16, 2010
Base term, 20 years from filing
Today
Term ended Oct 18, 2022
2002
2026
Clock starts
Oct 18, 2002
Oct 18, 2002
Term ended
Oct 18, 2022
Oct 18, 2022
Granted
Feb 16, 2010
Feb 16, 2010
base term
after the term ends
fee events
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 7,056,500, to Oct 18, 2022. The term already ends on or before that date, so the cap shortened nothing.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
17
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. All three maintenance fees were paid, so no fee lapse ended it. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Oct 18, 2002, when application 10/274,296, the earliest non-provisional in its chain, was filed (this one was filed Jan 17, 2006) | Oct 18, 2022 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 7,056,500) | resolves to Oct 18, 2022, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | term ended | High confidence |
| Computed term end | The steps above, in order | Oct 18, 2022 | High confidence |
This family
| US 7,056,500 | Term ended Jun 2024 | Jun 2024 |
| US 7,786,133 | In force Sep 2028 | Sep 2028 |
| US 7,662,365 | this patent Oct 2022 | Oct 2022 |
| Application 11/344,404 | Abandoned not computed | not computed |
| Application PCT/US2007/009761 | PCT application no patent term | no patent term |
| US 8,183,376 | In force Nov 2028 | Nov 2028 |
| US 8,349,307 | Term ended Oct 2022 | Oct 2022 |
| US 8,067,431 | Term ended Feb 2025 | Feb 2025 |
8 of 17 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Aug 31, 2009 Reel 23196, frame 394 | Nektar Therapeutics Al, Corporation | Nektar Therapeutics | Merger |
| Jul 17, 2012 Reel 28571, frame 141 | Nektar Therapeutics | Wells Fargo Bank, National Association, as Collateral Agent | Grant of Security Interest |
| Mar 11, 2013 Reel 29964, frame 920 | Wells Fargo Bank, National Association, as Collateral Agent | Nektar Therapeutics | Partial Release of Patents |
| Mar 12, 2015 Reel 35155, frame 759 | Bentley, Michael David; Roberts, Michael James; Shen, Xiaoming; Cheng, Lin | Nektar Therapeutics Al, Corporation | Assignment of Assignor's Interest |
| Oct 6, 2015 Reel 36796, frame 562 | Nektar Therapeutics | TC Lending, LLC, as Collateral Agent | Grant of Security Interest in United States Patents |
| Oct 14, 2015 Reel 36866, frame 700 | Wells Fargo Bank, National Association, as Collateral Agent | Nektar Therapeutics | Release of Security Interest Recorded at Reel 28571, Frame 0141 |
| Feb 24, 2020 Reel 51909, frame 460 | Redhill Biopharma Inc. | HCR Collateral Management, LLC, as Administrative Agent | Security Interest |
| Apr 17, 2020 Reel 53180, frame 9 | TC Lending, LLC, as Collateral Agent | Nektar Therapeutics | Release of Security Interest |
| Jul 19, 2024 Reel 68034, frame 458 | HCR Redhill SPV, LLC | Redhill Biopharma Inc.; Redhill Biopharma Ltd. | Release of Security Interest |
| Jul 19, 2024 reel/frame not recorded | HCR Redhill SPV, LLC | Redhill Biopharma Inc. | Release of Security Interest |
| Jul 19, 2024 reel/frame not recorded | HCR Redhill SPV, LLC | Redhill Biopharma Ltd. | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 7,056,500, ends no earlier than this term, so it caps nothing.
Citations
67
later US patents cite this one
That is top 10% of utility patents granted in 2010 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.